01:39 PM EST, 01/16/2025 (MT Newswires) -- Charles River Laboratories ( CRL ) and Akron Bio said Thursday they integrated Akron's current Closed System Solutions liquid cytokines into Charles River's Cell Therapy Flex Platform to improve cancer treatment platform.

Using closed systems can simplify the production process, minimize risk, and boost the overall reliability of cell therapy manufacturing, the company said.

Adding liquid cytokines to the Flex Platform could reduce labor requirements, strengthen processes, and ultimately lower risks for patients, Charles River's Senior Vice President Kerstin Dolph added.

Price: 165.26, Change: -8.65, Percent Change: -4.97